低分化甲状腺癌合并Graves病致T3型甲状腺毒症:D1和D2活性增高
本文报告一例77岁男性低分化甲状腺癌合并Graves病,表现为T3型甲状腺毒症。肿瘤组织D1和D2活性较左甲状腺叶增高,导致血清fT3/fT4比值升高。
要点
- 低分化甲状腺癌可合并Graves病并出现T3型甲状腺毒症。
- 肿瘤组织D1和D2活性增高导致fT3/fT4比值升高。
- 甲状腺毒症患者需警惕合并甲状腺恶性肿瘤的可能。
核心结论
- 低分化甲状腺癌中D1和D2活性增高可导致T3型甲状腺毒症,表现为血清fT3/fT4比值升高。
研究设计与样本
- 个案报道:一例77岁男性低分化甲状腺癌合并Graves病患者。
主要发现
- 超声显示右叶220 mL肿块,实验室检查示TSH低、fT4低、fT3高,TRAb和TSAb阳性。
- 131I显像仅左叶弥漫性摄取,全甲状腺切除术后组织学诊断为低分化甲状腺癌。
- 肿瘤组织D1和D2活性较左甲状腺叶增高。
临床怎么用
- 对甲状腺毒症患者应评估是否存在甲状腺肿瘤,尤其是T3型甲状腺毒症伴fT3/fT4比值升高时。
局限性
- 单例个案报道,结论推广受限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Poorly differentiated thyroid carcinoma is rare and patients are typically euthyroid. We report a novel rare case of poorly differentiated thyroid carcinoma with triiodothyronine (T3) thyrotoxicosis. Patient's Findings: A 77-year-old man presented to Kuma Hospital due to a neck tumor. A thyroid ultrasonography revealed a 220-mL mass in the right lobe. Laboratory data showed low serum thyrotropin (TSH), low free thyroxine (fT4), and high free T3 (fT3) levels. Anti-TSH receptor antibodies and thyroid-stimulating antibodies were positive. 131I scintigraphy showed diffuse uptake only in the left thyroid lobe. The patient underwent a total thyroidectomy and histological examination identified as poorly differentiated thyroid carcinoma. He was diagnosed with poorly differentiated thyroid carcinoma coexisting with Graves' disease. The tumor showed elevated type 1 iodothyronine deiodinases (D1) and type 2 iodothyronine deiodinases (D2) activities compared with that of the left thyroid lobe. Summary and Conclusions: Increased D1 and D2 activities in poorly differentiated carcinoma resulted in T3 toxicosis with a high serum fT3/fT4 ratio.
引用
- Okazaki-Hada M, Maruoka A, Yamamoto M, et al. Poorly Differentiated Thyroid Carcinoma Coexisting with Graves' Disease Involving T3 Thyrotoxicosis due to Increased D1 and D2 Activities. Thyroid. 2021. PMID: 34278816. doi:10.1089/thy.2021.0082
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。